BR112016020822A2 - Métodos e composições para secreção de polipeptídeos heterólogos - Google Patents

Métodos e composições para secreção de polipeptídeos heterólogos

Info

Publication number
BR112016020822A2
BR112016020822A2 BR112016020822A BR112016020822A BR112016020822A2 BR 112016020822 A2 BR112016020822 A2 BR 112016020822A2 BR 112016020822 A BR112016020822 A BR 112016020822A BR 112016020822 A BR112016020822 A BR 112016020822A BR 112016020822 A2 BR112016020822 A2 BR 112016020822A2
Authority
BR
Brazil
Prior art keywords
secretion
compositions
methods
heterologous polypeptides
relates
Prior art date
Application number
BR112016020822A
Other languages
English (en)
Inventor
Reilly Dorothea
Zhou Yizhou
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112016020822A2 publication Critical patent/BR112016020822A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MÉTODOS E COMPOSIÇÕES PARA SECREÇÃO DE POLIPEPTÍDEOS HETERÓLOGOS. A presente invenção refere-se geralmente aos campos da biologia molecular e da tecnologia de proteínas. Mais especificamente, a invenção refere-se a sequências sinal para a secreção de polipeptídeo heterólogo a partir de bactérias. A invenção também refere-se a polipeptídeos recombinantes e seus usos.
BR112016020822A 2014-03-14 2015-03-16 Métodos e composições para secreção de polipeptídeos heterólogos BR112016020822A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461953629P 2014-03-14 2014-03-14
US201562107981P 2015-01-26 2015-01-26
US201562108476P 2015-01-27 2015-01-27
PCT/US2015/020783 WO2015139046A1 (en) 2014-03-14 2015-03-16 Methods and compositions for secretion of heterologous polypeptides

Publications (1)

Publication Number Publication Date
BR112016020822A2 true BR112016020822A2 (pt) 2017-10-03

Family

ID=52829322

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016020822A BR112016020822A2 (pt) 2014-03-14 2015-03-16 Métodos e composições para secreção de polipeptídeos heterólogos

Country Status (18)

Country Link
US (2) US10435694B2 (pt)
EP (1) EP3116999B1 (pt)
JP (2) JP6644717B2 (pt)
KR (1) KR102561695B1 (pt)
CN (1) CN106103730B (pt)
AU (1) AU2015229035B2 (pt)
BR (1) BR112016020822A2 (pt)
CA (1) CA2941687A1 (pt)
ES (1) ES2897765T3 (pt)
HR (1) HRP20211748T1 (pt)
IL (1) IL247632B (pt)
MA (1) MA39746A (pt)
MX (2) MX2016011637A (pt)
PL (1) PL3116999T3 (pt)
RU (1) RU2748026C2 (pt)
SG (1) SG11201607519VA (pt)
SI (1) SI3116999T1 (pt)
WO (1) WO2015139046A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10435694B2 (en) * 2014-03-14 2019-10-08 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
CN109863247A (zh) * 2016-10-27 2019-06-07 免疫医疗有限责任公司 用于改善的蛋白质的分泌的信号多肽
CN106676122B (zh) * 2017-01-24 2019-10-29 成都分子脉象生物科技有限公司 一种基于AraF信号肽的双功能DNA元件及其应用
WO2018211936A1 (ja) 2017-05-19 2018-11-22 真吾 前田 Ｃｃｒ４阻害による制御性ｔ細胞浸潤抑制法およびイヌの腫瘍性疾患の治療法
GB201708277D0 (en) * 2017-05-24 2017-07-05 Ge Healthcare A Recombinant protein
KR101946789B1 (ko) * 2018-01-26 2019-02-12 (주)휴온스 이황화결합 이성질화효소 신호 펩타이드를 포함하는 재조합 벡터 및 이의 용도
EP3898982A2 (en) * 2018-12-19 2021-10-27 Versameb AG Rna encoding a protein
KR20220031670A (ko) * 2019-08-05 2022-03-11 와커 헤미 아게 발효 방법에서 재조합 단백질 방출용 박테리아 균주
WO2021158163A1 (en) * 2020-02-07 2021-08-12 Xbrane Biopharma Ab Synthetically evolved dna constructs for regulating signal peptide performance as well as vectors, host cells and recombinant proteins thereof
SE544059C2 (en) * 2020-02-07 2021-11-30 Cloneopt Ab Synthetically evolved dna constructs for regulating signal peptide performance as well as vectors and host cells thereof
SE543945C2 (en) * 2020-02-07 2021-10-05 Cloneopt Ab Synthetically evolved DNA constructs for regulating signal peptide performance as well as vectors and host cells thereof
WO2023046930A1 (en) * 2021-09-24 2023-03-30 Xbrane Biopharma Ab Dna constructs and host cells for expressing recombinant protein

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3645090A (en) 1969-06-19 1972-02-29 Citizen Watch Co Ltd Day-date quick-adjuster for calender timepiece
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
AU668423B2 (en) 1992-08-17 1996-05-02 Genentech Inc. Bispecific immunoadhesins
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6242177B1 (en) 1995-03-01 2001-06-05 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5747662A (en) 1995-03-01 1998-05-05 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6027888A (en) 1996-04-05 2000-02-22 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
AU784045B2 (en) 1999-06-25 2006-01-19 Genentech Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP4668498B2 (ja) 1999-10-19 2011-04-13 協和発酵キリン株式会社 ポリペプチドの製造方法
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
AU784285B2 (en) 1999-12-24 2006-03-02 Genentech Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
CA2395832A1 (en) 2000-01-25 2001-08-02 Genentech, Inc. Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
US20020022659A1 (en) * 2000-07-19 2002-02-21 Harris Gregory D. Crystalline and salt forms of an HIV protease inhibitor
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
DK1341899T3 (da) 2000-12-14 2006-04-10 Genentech Inc Bakterieværtsstammer
KR100879194B1 (ko) 2000-12-14 2009-01-16 제넨테크, 인크. 원핵생물에 의해 제조된 항체 및 이의 용도
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
MXPA04001566A (es) 2001-08-27 2004-05-17 Genentech Inc Un sistema para expresion y ensamblado de anticuerpos.
EP1908769A1 (en) * 2001-08-27 2008-04-09 Genentech, Inc. A system for antibody expression and assembly
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
WO2003085118A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
BRPI0316779B1 (pt) 2002-12-16 2020-04-28 Genentech Inc anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
KR100570422B1 (ko) 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
RS58420B1 (sr) 2003-11-05 2019-04-30 Roche Glycart Ag Cd20 antitela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
BRPI0516572A (pt) 2004-10-05 2008-09-16 Wyeth Corp métodos e composições para melhorar a produção de proteìnas recombinantes
RU2404193C2 (ru) 2005-03-25 2010-11-20 Дженентек, Инк. Способ лечения опухоли у субъекта
DK1902131T3 (da) 2005-07-08 2010-03-01 Univ Zuerich Fag-display under anvendelse af cotranslational translokation af fusionspolypeptider
CN100475965C (zh) 2005-07-22 2009-04-08 上海高科联合生物技术研发有限公司 一种大肠杆菌高效外分泌表达溶葡萄球菌酶的方法
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008089132A2 (en) 2007-01-12 2008-07-24 Cornell Research Foundation, Inc. Genetic selection for protein folding and solubility in the bacterial periplasm
EP2468869B1 (en) 2007-01-31 2015-03-18 Pfenex Inc. Bacterial leader sequences for increased expression
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
WO2009021548A1 (en) * 2007-08-10 2009-02-19 Wacker Chemie Ag Expression of full length igg and secretion into the culture medium of prokaryotic cells
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
BRPI0906099A2 (pt) 2008-03-06 2015-07-21 Genentech Inc "método de tratamento do câncer em um indivíduo"
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
US9388406B2 (en) * 2008-11-17 2016-07-12 Cornell University System useful for reporting protein-protein interactions in the bacterial periplasm
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
KR101968766B1 (ko) 2009-11-05 2019-04-12 제넨테크, 인크. 이종 폴리펩티드의 분비를 위한 방법 및 조성물
SG10201408229WA (en) 2010-08-31 2015-02-27 Genentech Inc Biomarkers and methods of treatment
US20130004481A1 (en) 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
MX2013014687A (es) 2011-06-30 2014-02-17 Genentech Inc Formulaciones de anticuerpo anti-c-met.
CN103930111A (zh) 2011-09-19 2014-07-16 霍夫曼-拉罗奇有限公司 包含c-met拮抗剂和b-raf拮抗剂的组合治疗
CN104066748A (zh) 2011-11-21 2014-09-24 霍夫曼-拉罗奇有限公司 抗c-met抗体的纯化
US10435694B2 (en) 2014-03-14 2019-10-08 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides

Also Published As

Publication number Publication date
US10435694B2 (en) 2019-10-08
RU2748026C2 (ru) 2021-05-19
PL3116999T3 (pl) 2021-12-27
WO2015139046A1 (en) 2015-09-17
ES2897765T3 (es) 2022-03-02
US11390872B2 (en) 2022-07-19
SI3116999T1 (sl) 2021-12-31
US20170029825A1 (en) 2017-02-02
JP2017510294A (ja) 2017-04-13
US20200181625A1 (en) 2020-06-11
CN106103730B (zh) 2021-06-08
MX2016011637A (es) 2017-04-13
CN106103730A (zh) 2016-11-09
HRP20211748T1 (hr) 2022-02-18
AU2015229035A1 (en) 2016-09-22
AU2015229035B2 (en) 2021-08-05
EP3116999A1 (en) 2017-01-18
KR20160134758A (ko) 2016-11-23
IL247632A0 (en) 2016-11-30
IL247632B (en) 2021-02-28
MX2021001460A (es) 2021-04-28
JP6644717B2 (ja) 2020-02-12
EP3116999B1 (en) 2021-09-15
CA2941687A1 (en) 2015-09-17
SG11201607519VA (en) 2016-10-28
MA39746A (fr) 2021-04-28
RU2016140244A (ru) 2018-04-17
JP2020078305A (ja) 2020-05-28
KR102561695B1 (ko) 2023-07-28
RU2016140244A3 (pt) 2019-05-22

Similar Documents

Publication Publication Date Title
BR112016020822A2 (pt) Métodos e composições para secreção de polipeptídeos heterólogos
AU2019284081A1 (en) Food compositions comprising recombinant milk proteins and methods of producing the same
ZA202201361B (en) Methods and compositions comprising purified recombinant polypeptides
NZ746934A (en) Cd80 variant immunomodulatory proteins and uses thereof
BR112018004965A2 (pt) domínios de superfamìlia de imunoglobulina variante ajustàvel
MX2023011785A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
MY181199A (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
SG10201909716RA (en) Modified j-chain
EA202192126A3 (ru) Способы сбора культур клеток млекопитающих
MX2015011951A (es) Proteinas de fusion que comprenden partes de union a pdgf y vegf y metodos de uso de las mismas.
DK3253402T3 (da) Rekombinante probiotiske bakterier
EP3236772A4 (en) Methods of purifying recombinant proteins
MX2017008643A (es) Proteina de fusion que comprende un dominio de union a ligando de factor de crecimiento endotelial vascular (vegf) y factor de crecimiento derivado de plaquetas (pdgf).
WO2016022377A3 (en) Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
EA201890914A1 (ru) Доставка белка бактериями
EP3448884C0 (en) MANIPULATED MAMMALIAN CELLS FOR THE PRODUCTION OF RECOMBINANT PROTEINS
IL262752B (en) Construction of transgenic bacteria for high expression of recombinant albumin from human serum
EP3436484A4 (en) RECOMBINANT INTRAVENOUS IMMUNOGLOBULIN (RIVIG) COMPOSITIONS AND METHODS OF MAKING AND USING THEM
EA202190244A3 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
BR112018009097A2 (pt) spodoptera frugiperda resistente a vip3a
BR112015004629A2 (pt) polipeptídeos de clostridium difficile como vacinas
EA202091567A1 (ru) Химерные белки мти
MX2018007298A (es) Variantes con mejores propiedades de polipéptidos de fusión relacionados con omega-hidroxilasa.
EP3125923A4 (en) Lyophilized pharmaceutical composition of fc-peptide fusion protein

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements